{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T07:01:43Z","timestamp":1767942103124,"version":"3.49.0"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development and Commercialization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nephrol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunoglobulin A nephropathy (IgAN) is a leading cause of chronic kidney disease (CKD) worldwide. While racial and ethnic differences in disease progression are well documented, the Hispanic\/Latinx populations remain understudied despite their elevated risk of kidney failure among other CKD populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the kidney function decline and progression in Hispanic\/Latinx patients with biopsy-proven IgAN within a large, integrated healthcare system and to contextualize to other racial\/ethnic groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective case series study of 259 Hispanic\/Latinx adults with biopsy-proven IgAN from the Kaiser Permanente Southern California (KPSC) health system. Patients were followed from biopsy to \u226550% decline in the estimated glomerular filtration rate (eGFR), kidney failure, mortality, the study end date of November 30, 2022, or disenrollment. Annualized eGFR decline and the incidence of composite kidney outcomes were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At diagnosis, Hispanic\/Latinx patients had significant CKD and a high risk of progression to kidney failure, indicated by a median eGFR of 56 ml min\n                      <jats:sup>\u22121<\/jats:sup>\n                      1.73 m\n                      <jats:sup>\u22122<\/jats:sup>\n                      and a median urine protein\/creatinine ratio of 1.8 g\/g. Common treatments included immunosuppressive agents (41%), angiotensin-converting enzyme (ACE) inhibitors (48%), and angiotensin receptor blockers (ARBs; 20%). The mean annual eGFR decline was \u22124.5 ml min\n                      <jats:sup>\u22121<\/jats:sup>\n                      1.73 m\n                      <jats:sup>\u22122<\/jats:sup>\n                      , and 30.9% experienced rapid decline (&amp;gt;5 ml min\n                      <jats:sup>\u22121<\/jats:sup>\n                      1.73 m\n                      <jats:sup>\u22122<\/jats:sup>\n                      per year). The composite kidney outcome occurred at 73.3 events per 1,000 patient-years, with a median time to event of 2.8 years and a median age at event of 46 years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Hispanic\/Latinx patients with IgAN demonstrate rapid kidney function decline and early-onset kidney failure. These findings underscore the need for earlier detection and targeted management in this underserved group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneph.2025.1744454","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T05:15:13Z","timestamp":1767935713000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Progression of immunoglobulin A nephropathy (IgAN) in a Hispanic\/Latinx population in the United States"],"prefix":"10.3389","volume":"5","author":[{"given":"John J.","family":"Sim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy T.","family":"Cannizzaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasikiran","family":"Nunna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohit","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cibele","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: a systematic review of the literature","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr527","article-title":"Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population","volume":"27","author":"Le","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1053\/j.ajkd.2023.12.016","article-title":"Time-varying proteinuria and progression of IgA nephropathy: a cohort study","volume":"84","author":"Tang","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000000000165","article-title":"Global incidence of IgA nephropathy by race and ethnicity: a systematic review","volume":"4","author":"Kiryluk","year":"2023","journal-title":"Kidney360"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.210","article-title":"Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease","volume":"84","author":"Barbour","year":"2013","journal-title":"Kidney Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(00)70258-7","article-title":"Changing incidence of glomerular diseases in adults","volume":"35","author":"Braden","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1590\/s1516-31802009000300006","article-title":"Glomerular diseases in a Hispanic population: review of a regional renal biopsy database","volume":"127","author":"Arias","year":"2009","journal-title":"Sao Paulo Med J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2018.02.354","article-title":"CKD and ESRD in US hispanics","volume":"73","author":"Desai","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7812\/TPP\/12-031","article-title":"Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data","volume":"16","author":"Koebnick","year":"2012","journal-title":"Perm J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf084","article-title":"CKD progression, kidney failure, and mortality among US patients with IgA nephropathy","author":"Sim","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1159\/000541869","article-title":"Incidence of adult primary immunoglobulin A nephropathy among a racially\/ethnically diverse population in the United States","volume":"56","author":"Sim","year":"2025","journal-title":"Am J Nephrol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/kisup.2012.65","article-title":"Chapter 2: Definition, identification, and prediction of CKD progression","volume":"3","year":"2013","journal-title":"Kidney Int Suppl (2011)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-010-1335-8","article-title":"Hypertension and diabetes prevalence among U.S. Hispanics by country of origin: the National Health Interview Survey 2000-2005","volume":"25","author":"Pabon-Nau","year":"2010","journal-title":"J Gen Intern Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","author":"Rovin","year":"2025","journal-title":"Kidney Int"}],"container-title":["Frontiers in Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2025.1744454\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T05:15:14Z","timestamp":1767935714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2025.1744454\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":16,"alternative-id":["10.3389\/fneph.2025.1744454"],"URL":"https:\/\/doi.org\/10.3389\/fneph.2025.1744454","relation":{},"ISSN":["2813-0626"],"issn-type":[{"value":"2813-0626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"article-number":"1744454"}}